EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Diving into drug-screening: zebrafish embryos as an in vivo platform for antimicrobial drug discovery and assessment

Eva Habjan iD, Gina K Schouten iD, Alexander Speer iD, Peter van Ulsen iD, Wilbert Bitter iD

FEMS Microbiology Reviews · 2024

DOI: 10.1093/femsre/fuae011 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift FEMS Microbiology Reviews, 2024. Verfasst von Eva Habjan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology and Infection Control, Amsterdam UMC, Location VU Medical Center,De Boelelaan 1108, 1081 HZ Amsterdam, The Netherl…. Hauptthemen laut MEDLINE: Zebrafish, Drug Discovery, Drug Evaluation, Preclinical, Embryo, Nonmammalian. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NWO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rise of multidrug-resistant bacteria underlines the need for innovative treatments, yet the introduction of new drugs has stagnated despite numerous antimicrobial discoveries. A major hurdle is a poor correlation between promising in vitro data and in vivo efficacy in animal models, which is essential for clinical development. Early in vivo testing is hindered by the expense and complexity of existing animal models. Therefore, there is a pressing need for cost-effective, rapid preclinical models with high translational value. To overcome these challenges, zebrafish embryos have emerged as an attractive model for infectious disease studies, offering advantages such as ethical alignment, rapid development, ease of maintenance, and genetic manipulability. The zebrafish embryo infection model, involving microinjection or immersion of pathogens and potential antibiotic hit compounds, provides a promising solution for early-stage drug screening. It offers a cost-effective and rapid means of assessing the efficacy, toxicity and mechanism of action of compounds in a whole-organism context. This review discusses the experimental design of this model, but also its benefits and challenges. Additionally, it highlights recently identified compounds in the zebrafish embryo infection model and discusses the relevance of the model in predicting the compound’s clinical potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ZebrafishDrug DiscoveryDrug Evaluation, PreclinicalEmbryo, NonmammalianAnimalsAnti-Bacterial AgentsDisease Models, AnimalAnti-Infective Agents

Stichwörter der Autor:innen

Danio rerioanimal modelsantimicrobialsdrug screeninginfection modelszebrafish embryo

Substanzen

Anti-Bacterial AgentsAnti-Infective Agents

Autor:innen und Institutionen

  • Department of Medical Microbiology and Infection Control, Amsterdam UMC, Location VU Medical Center,De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands.
  • Section Molecular Microbiology of A-LIFE, Vrije Universiteit, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands.

ORCID-Profile: Eva Habjan, Gina K Schouten, Alexander Speer, Peter van Ulsen, Wilbert Bitter

Förderung

  • NWO

Zitieren

APA

Habjan, E., Schouten, G. K., Speer, A., van Ulsen, P., & Bitter, W. (2024). Diving into drug-screening: zebrafish embryos as an in vivo platform for antimicrobial drug discovery and assessment. FEMS Microbiology Reviews. https://doi.org/10.1093/femsre/fuae011

Vancouver

Habjan E, Schouten GK, Speer A, van Ulsen P, Bitter W. Diving into drug-screening: zebrafish embryos as an in vivo platform for antimicrobial drug discovery and assessment. FEMS Microbiology Reviews. 2024. doi:10.1093/femsre/fuae011

BibTeX
@article{Habjan2024,
  author = {Habjan, Eva and Schouten, Gina K and Speer, Alexander and van Ulsen, Peter and Bitter, Wilbert},
  title = {Diving into drug-screening: zebrafish embryos as an in vivo platform for antimicrobial drug discovery and assessment},
  journal = {FEMS Microbiology Reviews},
  year = {2024},
  doi = {10.1093/femsre/fuae011}
}
Kostenlos starten →